ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,55
-0,80%
Dow Jones
40 211,72
0,53%
DAX
18 505,52
-0,51%
Brent Oil
83,315
-1,22%
Bitcoin
63 430,70
-2,19%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
07/11/202222h10TipRanksAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Quest Diagnostics (DGX) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202204h35TipRanksSVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
05/11/202221h00GlobeNewswire Inc.Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202215h01TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Fate Therapeutics (FATE) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202213h17TipRanksJ.P. Morgan Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202206h05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from JMP SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
03/11/202223h25TipRanksChardan Capital Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202221h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202212h41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202212h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
31/10/202212h30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
27/10/202213h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
26/09/202213h30GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
19/09/202214h45TipRanksIntellia Therapeutics (NTLA) Receives a Buy from SVB SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202223h05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from Chardan CapitalNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202222h05TipRanksJMP Securities Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
16/09/202217h58TipRanksPiper surprised by Intellia selloff, says data ‘checks all boxes’NASDAQ:NTLAIntellia Therapeutics Inc
16/09/202214h22TipRanksIntellia Therapeutics (NASDAQ: NTLA) Jumps After Positive Clinical DataNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202213h15PR Newswire (US)Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202213h00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
13/09/202214h20TipRanksAnalysts Conflicted on These Healthcare Names: Horizon Therapeutics (HZNP) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
12/09/202206h25TipRanksRobert W. Baird Releases a Hold Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
08/09/202222h01GlobeNewswire Inc.Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022NASDAQ:NTLAIntellia Therapeutics Inc
01/09/202222h55Dow Jones NewsIntellia Therapeutics' NTLA-2002 Genome Candidate Receives FDA's Orphan Drug DesignationNASDAQ:NTLAIntellia Therapeutics Inc
01/09/202222h01GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
26/08/202214h16TipRanksBMO Capital Remains a Hold on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
23/08/202215h59GlobeNewswire Inc.Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin SymposiumNASDAQ:NTLAIntellia Therapeutics Inc
09/08/202206h11TipRanksWhich 3 ARK Innovation Stocks Can Bounce the Most?NASDAQ:NTLAIntellia Therapeutics Inc
08/08/202218h00TipRanksAnalysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Crispr Therapeutics AG (CRSP)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202214h35TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

NASDAQ
SABR
Sabre
NASDAQ
CSCD
USOTC
ALIZF
Allianz Ag Muenchen Namen (PK)
TSXV
GBR
Great Bear Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés